menu
    • menu

    Company profile for Ixaka

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ixaka (formerly Rexgenero) is a private UK-based cell and gene therapy company with operations in the UK, Spain and France. The company is focused on the natural power of the body to cure disease. Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action. Ixaka’s technolo...
    Ixaka (formerly Rexgenero) is a private UK-based cell and gene therapy company with operations in the UK, Spain and France. The company is focused on the natural power of the body to cure disease. Our proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and by directly modifying cells within the body to improve their therapeutic action. Ixaka’s technologies – concentrated multi-cell therapies and targeted nano-particles – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ixakaunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    45 Pont Street London SW1X 0BD
    Telephone
    Telephone
    +44 203 7007 480
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ixaka.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ixaka Expands IP Portfolio to Enable Use of Nanoparticle in vivo Gene Delivery
    Ixaka Expands IP Portfolio to Enable Use of Nanoparticle in vivo Gene Delivery

    21 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220321005423/en

    BUSINESSWIRE
    21 Mar 2022
    Share Share
    Cell door: EMA grants ATMP classification to CELTIC-19
    Cell door: EMA grants ATMP classification to CELTIC-19

    08 Mar 2022

    // PHARMATIMES

    https://www.pharmatimes.com/news/cell_door_ema_grants_atmp_classification_to_celtic-19_1388660

    PHARMATIMES
    08 Mar 2022
    Share Share
    CELTIC-19 Granted ATMP Classification by European Medicines Agency
    CELTIC-19 Granted ATMP Classification by European Medicines Agency

    07 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220308005306/en

    BUSINESSWIRE
    07 Mar 2022
    Share Share
    Ixaka Expands Management Team with Multiple Appointments
    Ixaka Expands Management Team with Multiple Appointments

    10 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220210005479/en

    BUSINESSWIRE
    10 Feb 2022
    Share Share
    Ixaka announces positive interim Ph3 clinical trial data for REX-001
    Ixaka announces positive interim Ph3 clinical trial data for REX-001

    08 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210908005118/en/Ixaka-announces-positive-interim-Phase-3-clinical-trial-data-for-its-lead-cell-therapy-candidate-REX-001

    BUSINESSWIRE
    08 Sep 2021
    Share Share
    Positive interim data for Ixaka’s lead ‘multi-cell’ therapy
    Positive interim data for Ixaka’s lead ‘multi-cell’ therapy

    08 Sep 2021

    // Lucy Parsons PHARMA TIMES

    https://www.pharmatimes.com/news/positive_interim_data_for_ixakas_lead_multi-cell_therapy_1376392

    Lucy Parsons PHARMA TIMES
    08 Sep 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search